Treatment of diabetes

• US 20060189520A1
• Filed: 10/22/2003
• Published: 08/24/2006
• Est. Priority Date: 10/22/2002
• Status: Abandoned Application

• Current Assignee: Waratah Pharmaceuticals, Inc. (Opko Health, Inc.)
• Original Assignee: Waratah Pharmaceuticals, Inc. (Opko Health, Inc.)
• Inventors: Cruz, Antonio, Brand, Stephen J., Pastrak, Aleksandra
• Application Number:
  US10/532,295
• Publication Number:
  US 20060189520A1
• Time in Patent Office: Days
• US Class Current: 424/85.100
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/595 Gastrins; Cholecystokinins [CCK]

Abstract

Compositions and methods are provided for islet neogenesis therapy comprising a member of a group of factors that complement a gastrin/CCK receptor ligand, with formulations, devices and methods for sustained release delivery and for local delivery to target organs.

Claims

5. A method for treating diabetes, the method comprising:

contacting ex vivo a plurality of cells with a composition comprising at least one FACGINT and a gastrin/CCK receptor ligand, provided that the FACGINT is not an EGF receptor ligand; and

administering the cells to a mammal in need thereof, thereby treating the diabetes.

6-8. -8. (canceled)

11-12. -12. (canceled)

14-15. -15. (canceled)

16. A composition comprising a gastrin/CCK receptor ligand and a factor for complementing gastrin for islet neogenesis therapy (a FACGINT), provided that the FACGINT is not an EGF receptor ligand.

1. A method for treating diabetes, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a composition according to claim 16.

2. A method according to claim 1, wherein the FACGINT is at least one factor selected from the group consisting of a Glucagon-like peptide 1 receptor ligand;

a Glucagon-like peptide 2 receptor ligand;

a gastric inhibitory polypeptide (GIP) receptor ligand;

a keratinocyte growth factor (KGF) receptor ligand;

a dipeptidyl peptidase IV inhibitor;

a REG protein receptor ligand;

a Growth Hormone receptor ligand;

a Prolactin (PRL) receptor ligand;

an Insulin-like Growth Factor (IGF) receptor ligand;

PTH-related protein (PTHrP) receptor ligand;

hepatocyte growth factor (HGF) receptor ligand;

a bone morphogenetic protein (BMP) receptor ligand, a transforming growth factor-β

(TGF-β

) receptor ligand;

a laminin receptor ligand;

vasoactive intestinal peptide (VIP) receptor ligand;

a fibroblast growth factor (FGF) receptor ligand;

a nerve growth factor (NGF) receptor ligand;

an islet neogenesis associated protein (INGAP) receptor ligand;

an Activin-A receptor ligand;

a vascular endothelial growth factor (VEGF) receptor ligand;

an erythropoietin (EPO) receptor ligand;

a pituitary adenylate cyclase activating polypeptide (PACAP) receptor ligand;

a granulocyte colony stimulating factor (G-CSF) receptor ligand;

a granulocyte-macrophage colony stimulating factor (GM-CSF);

a platelet-derived growth factor (PDGF) receptor ligand; and

a Secretin receptor ligand.

3. A method according to claim 1, wherein the FACGINT comprises a Glucagon 1-like peptide receptor ligand which is a GLP-1 or exendin-4.

4. A method according to claim 2, wherein the FACGINT comprises a Growth Hormone.

9. The method according to claim 1, wherein the amount of the FACGINT in the composition is substantially less than the minimum effective dose of the FACGINT required to reduce blood glucose in the diabetic mammal in the absence of a gastrin/CCK receptor ligand.

10. The method according to claim 1, further comprising measuring a parameter selected from the group consisting of:

blood glucose, serum glucose, blood glycosylated hemoglobin, pancreatic P cell mass, serum insulin, pancreatic insulin content, morphometrically determined P cell mass, amount of insulin secreting cells, glucose responsiveness of insulin secreting cells, amount of proliferation of islet precursor cells, and amount of mature insulin secreting cells.

13. A method for increasing proliferation of pancreatic islet precursor cell proliferation in a mammal, the method comprising administering to the mammal a composition according to claim 16 in an amount sufficient to increase proliferation of islet precursor cells in pancreatic tissue of said mammal.

17. A composition according to claim 16 in a dosage effective for inducing differentiation of an islet precursor cell into a mature insulin secreting cell.

19. A kit for treating or preventing diabetes, the kit comprising a composition according to claim 16, a container, and instructions for use.

21. A method for expanding and differentiating stem cells into insulin secreting cells in a diabetic recipient of implanted cells, comprising implanting stem cells in the recipient, and administering to the recipient a composition according to claim 16.

47. A composition according to claim 16 further comprising an agent for immune suppression.

48. A composition according to claim 16 for sustained release wherein at least one of the gastrin receptor ligand or FACGINT is a sustained release formulation.

91. A method according to claim 21 wherein the composition is a sustained release composition comprising an effective dose of each of:

a gastrin/CCK receptor ligand; and

a FACGINT, wherein the stem cells are expanded and differentiated into insulin secreting cells in the recipient.

92. A composition according to claim 16 for treating diabetes, said composition comprising a Glucagon-like peptide-1 (GLP-1) receptor ligand and a gastrin/CCK receptor ligand.

98. The composition according to claim 92, wherein the gastrin is gastrin I having 17 amino acids with a Leu residue at amino acid position 15.

101. A method of treating a diabetic subject comprising administering to the subject a composition according to claim 92.

108. A method according to claim 21 wherein the cells are purified pancreatic islet cells and the functional β

cell mass of the pancreatic islet cells is expanded in the recipient.

18. (canceled)

20. (canceled)

22-31. -31. (canceled)

32. A method for reducing an amount of stem cells needed for transplantation to treat human diabetes, the method comprising administering to a recipient in need thereof an effective dose of each of a gastrin/CCK receptor ligand and a FACGINT provided that the FACGINT is not an EGF receptor ligand, wherein the amount of cells needed is reduced in comparison to an amount of cells needed in the absence of administering the effective dose to an otherwise identical recipient.

33-46. -46. (canceled)

49-90. -90. (canceled)

93-97. -97. (canceled)

99-100. -100. (canceled)

102-107. -107. (canceled)

109-110. -110. (canceled)